Clinical Report: Longitudinal Analysis of MASLD Patterns and Liver Cancer Risk

Overview

This study investigates the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and liver cancer incidence using data from the UK Biobank.

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver disorder linked to hepatocellular carcinoma (HCC). This study addresses the gap in knowledge regarding the prognostic value of repeated MASLD assessments in predicting liver cancer outcomes.

Data Highlights

Key Findings

• At baseline, 33.1% of participants had MASLD.
• MASLD at period 1 was associated with a higher risk of incident liver cancer (aHR, 2.81).
• MASLD at period 2 also indicated increased liver cancer risk (aHR, 2.61).
• Trajectory analysis showed that persistent MASLD (MASLD → MASLD) significantly increased liver cancer risk (aHR, 3.51).
• Prior MASLD exposure (MASLD → no MASLD) was linked to a higher risk of liver cancer (aHR, 4.00).

Clinical Implications

The findings suggest that clinicians should consider repeated assessments of MASLD in patients to better evaluate their risk for liver cancer. Understanding the trajectory of MASLD may aid in identifying individuals who require closer monitoring and intervention.

Conclusion

The study highlights the importance of both current and past MASLD status in assessing liver cancer risk.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Author(s)/Org, Source, Year -- Title
6. Author(s)/Org, Source, Year -- Title
7. Frontiers in Endocrinology — Metabolomic signatures mediate the association between physical frailty and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
8. EASL-EASD-EASO Clinical Practice Guidelines on MASLD
9. AASLD Practice Guidance on HCC
10. AGA Clinical Practice Update on Risk Stratification
11. Incidence of Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Reconstructed Individual Patient Data Meta-Analysis - Clinical Gastroenterology and Hepatology
12. Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease - PubMed
13. Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study - PubMed